The CEO of the pharmaceutical company said that there is a very high efficacy of the vaccine against the two new variants, both the United Kingdom and South Africa.
| 01/13/2021 | ionicons-v5-c10: 41 | . |
Brussels.- The CEO of the pharmaceutical Pfizer, Albert bourla, said this Wednesday that the vaccine against him Covid-19 that they have developed together with BioNTech has shown high efficacy against new variants of the virus in experiments carried out so far, although clinical results have yet to be analyzed to be certain.
« We have done several ‘in vitro’ experiments and there seems to be a very, very high efficacy of the vaccine of Pfizer/BioNTech compared to the two new variants, both the UK like the South Africa« Bourla said at a conference on the European Union and health organized by the European People’s Party (EPP).
This is « a very clear indication, but we have to also measure clinical results to be sure. But, in my opinion, I think the results will be very positive, » he added.
Bourla explained that right now the pharmaceutical company is analyzing whether, in addition to protecting against Covid-19, his vaccine avoid the virus transfer, something about which there are still no conclusive results.
In animals – he said – a « significant protection » has been detected in terms of virus transfer And, while it has not yet been tested in humans, Pfizer has « encouraging data » and could learn more in this regard next February.
The CEO of the US pharmaceutical company said that right now they are focusing their efforts on improving their ability to produce vaccine around the world and rely on « dramatically increasing » production.
« We hope to be able to deliver 2 billion doses this year, compared to the 1.3 billion we had before, and the efforts do not stop, » said Bourla, who blamed the bottlenecks on the fact that this is the first time this has been produced. vaccine and it is being done in extraordinary quantities.
The EU, he added, has acted « quite quickly, especially in this second phase », to secure a significant number of doses of the vaccine Pfizer/BioNTech, of which a good part will arrive soon.
Specifically, the European Commission negotiated before the effectiveness of the vaccine a contract to obtain 200 million doses of it, with the additional option of receiving another 100 million.
Brussels implemented this option after authorizing the use of the vaccine in the EU and, of these 100 million, 50 million doses will be delivered in the second quarter of 2021, according to Bourla.
In January, the Commission closed a new agreement to obtain an additional 300 million and, of this, 75 million will also arrive in the second quarter of the year.
These amounts are in addition to the doses that are already arriving for vaccination campaigns in different European countries, where criticism has come due to the slowness of the immunization effort.
Bourla said, on the other hand, that they are evaluating whether it is possible « to produce some version that can be published » of the contracts signed between Pfizer and BioNTech and the EU since, although these are confidential, in Europe « it has become a very sensitive issue ».